← All trials
NCT05465174
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2022
- Primary completion
- Mar 1, 2027
- Completion date
- Mar 1, 2028
- First posted
- Jul 19, 2022
- Last posted
- Nov 7, 2022
- Enrollment
- 56
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of PennsylvaniaStudy chair
- Day One Biopharmaceuticals, Inc.Collaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
- University of PennsylvaniaOfficial
- University of California, San FranciscoOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.